{
    "3963": "when not all exacerbation events occurred during the viral infection",
    "3855": "viral infection increases airway inflammation which aggravates disease symptoms",
    "3856": "novel human and animal challenge models",
    "3854": "Respiratory virus infection",
    "3857": "To elucidate the host airway interaction with viruses leading to exacerbations",
    "3858": "the prevalence of different respiratory viral infections",
    "3859": "These classical mechanisms of viral induced acute exacerbations",
    "3860": "recent data regarding viral interactions with the airway epithelium",
    "3861": "the understanding of viral induced exacerbation in chronic airway inflammatory diseases",
    "3862": "airway remodeling",
    "3863": "in both the upper airway",
    "3864": "the complexity and heterogeneity of the disease",
    "3865": "the increased susceptibility of chronic airway inflammatory disease patients toward viral respiratory infections",
    "3866": "high morbidity and even mortality worldwide",
    "3867": "the main cause of morbidity and sometimes mortality in patients",
    "3869": "the presence of environmental factors",
    "3870": "infiltration of activated immune cells",
    "3871": "viral infection",
    "3872": "having been detected in 30-80% of acute COPD exacerbations",
    "3873": "their ease of transmission and infection",
    "3874": "their ease of transmission and infection",
    "3875": "in order to properly manage exacerbations via supplementary treatments",
    "3876": "dysregulated inflammation in most chronic airway inflammatory diseases",
    "3877": "the upper airway",
    "3878": "To elucidate the host airway interaction with viruses leading to exacerbations",
    "3879": "\n",
    "3880": "bacterial infections",
    "3881": "more viruses were recovered during acute exacerbations events",
    "3882": "RV, RSV, and IFV",
    "3883": "RV, RSV, and IFV",
    "3884": "herpes simplex virus (HSV)",
    "3885": "they can infect both the upper and/or lower air",
    "3886": "airway epithelial cells",
    "3887": "the cells release antiviral factors and cytokines",
    "3888": "type 1 inflammatory responses",
    "3891": "impaired or aberrant",
    "3892": "recent findings of viral interaction with the upper airway",
    "3893": "consolidates the understanding of viral induced exacerbation in chronic airway inflammatory diseases",
    "3894": "current scarcity of antiviral drugs for the management of viral-induced exacerbations",
    "3941": "viruses evoke an inflammatory response as a means of counteracting the infection",
    "3942": "release",
    "3943": "viral exacerbation in chronic airway inflammatory diseases",
    "3944": "enhance granulocyte infiltration thus prolonging the exacerbation symptoms",
    "3945": "promote a Type 2-biased immune response",
    "3946": "worsens the classical symptoms of disease",
    "3947": "are more neutrophilic in nature",
    "3948": "IL-25, IL-33 and TSLP",
    "3949": "ILC2s are a group of lymphoid cells",
    "3950": "massive damage",
    "3951": "work in concert to activate ILC2s to further secrete",
    "3952": "increased ILC2 activation",
    "3954": "do not activate an ILC2 response",
    "3960": "heighten expression in an inflamed airway",
    "3961": "worsens the symptoms of airway diseases",
    "3962": "the increased susceptibility of chronic airway inflammatory disease patients toward viral respiratory infections",
    "3964": "as the nasal epithelium remains the primary site of most infections",
    "3965": "a more complex interplay between the virus and upper airway epithelium",
    "3966": "greatly affect the patients' quality of life",
    "3967": "high morbidity and even mortality worldwide",
    "3968": "to determine the contribution of the microbiome and mycobiome to viral infections",
    "3969": "recent data regarding viral interactions with the airway epithelium",
    "3970": "Patients with chronic airway inflammatory diseases",
    "3971": "a type 2-skewed inflammatory response",
    "3972": "in weak type 1 inflammation-inducing viruses such as RV and RSV",
    "3973": "massive damage and cell death to the epithelial barrier,",
    "3974": "prolong airway inflammation",
    "3975": "enhance granulocyte infiltration thus prolonging the exacerbation symptoms",
    "3976": "human papilloma virus (HPV",
    "3977": "the role of HPV infection in causing chronic inflammation in the airway",
    "3978": "the development of steroid resistance",
    "3979": "cause the virus to linger longer in the airway",
    "3980": "acute exacerbation",
    "3981": "19 virus)",
    "3982": "massive damage and cell death to the epithelial barrier",
    "3983": "further compounds the cell deaths in IFV infected epithelium",
    "3984": "further contact with other pathogens and allergens in the airway",
    "3985": "promote further epithelial remodeling during its regeneration",
    "3986": "receive their annual influenza vaccination",
    "3987": "the induction of vasodilation or tight junction opening factors",
    "3988": "disruption of tight junctions",
    "3989": "weak type 1 inflammation-inducing viruses",
    "3990": "oxidative stress",
    "3991": "the relationship between asthma and COPD exacerbations",
    "3992": "bacterial species in the microbiome which may thrive in the inflamed airway environment",
    "3993": "the effect induced by the virus may destabilize the equilibrium of the microbiome present",
    "3994": "the epithelial barrier in the airways, the upper airway microbial environment",
    "3995": "impaired bacterial immune response",
    "3996": "more far reaching effect when normal flora is replaced with opportunistic pathogens",
    "3997": "due to the complex interactions between the host and the exacerbation agents",
    "3998": "shown efficacy in the treatments of irritable bowel syndrome by restoring the intestinal microbiome",
    "3999": "increase neutrophilic activation",
    "4000": "upper airway epithelium",
    "4001": "may cause further contact with other pathogens and allergens in the airway",
    "4002": "oxidative stress",
    "4003": "modulation of miRNAs and epigenetic modification",
    "4004": "growth of pathogenic bacteria that may replace the airway microbiome",
    "4005": "inflammation and alteration of the lower airway environment",
    "4006": "RV, RSV, and IFV",
    "4007": "promote a Type 2-biased immune response",
    "4008": "disrupt the equilibrium of the mucociliary function following viral infection",
    "4009": "symptoms of acute exacerbation",
    "4010": "are short non-coding RNAs",
    "4011": "viral infections",
    "4012": "circulating miRNA changes",
    "4013": "the infected epithelium and responding immune cells",
    "4014": "to increase miR-21 and augmented inflammation in experimental murine asthma models",
    "4015": "induce oncostatin M (OSM) which causes tight junction opening (",
    "4016": "aberrant epithelial response, contributing to exacerbations",
    "4017": "targets to modulate viral induced airway changes",
    "4018": "epigenetic modification such as DNA methylation",
    "4019": "the association of epigenetic modification and chronic airway inflammatory diseases",
    "4020": "that viral infections",
    "4021": "that antiviral factors",
    "4022": "an altered inflammatory state",
    "4023": "increase neutrophilic activation",
    "4024": "constant oxidative stress",
    "4025": "trigger the further production of ROS as an antiviral mechanism",
    "4026": "infiltrating cells",
    "4027": "alter the management of the disease or confer resistance toward treatments that worked before",
    "4028": "important information",
    "4029": "epithelial cell models",
    "4030": "to identify systemic mechanisms of acute exacerbation",
    "4031": "humanized mouse model that possess human immune cells",
    "4032": "the best mode of verification of the associations of the virus",
    "3868": "due to the complex interactions between the host and the exacerbation agents",
    "3687": "long non-coding RNAs (lncRNAs)",
    "3688": "to calculate the relevance between lncRNA and protein in a heterogeneous network",
    "3689": "protein-protein interaction (PPI)",
    "3690": "regulates cell cycle and survival",
    "941": "RNA-Seq",
    "933": "by mosquitoes and that is naturally present in rodent reservoirs",
    "934": "fever, malaise, and vomiting",
    "935": "35%",
    "936": "10%",
    "937": "TC83",
    "938": "differential alterations in VEEV-infected astrocytes",
    "939": "endoplasmic reticulum (ER) stress",
    "940": "inositolrequiring enzyme 1 (IRE1), protein kinase RNA",
    "942": "Hs00152928_m1",
    "943": "a zinc finger protein and mammalian transcription factor",
    "557": "2012",
    "558": "21%",
    "559": "males more than females",
    "560": "Dromedary camels",
    "562": "11-13 days",
    "563": "16 days",
    "564": "supportive and symptomatic",
    "565": "between 41 and 60 years",
    "279": "Nod-like receptor family, pyrin domain-containing 3",
    "280": "in lipopolysaccharide-primed macrophages",
    "281": "activity of the 3a protein",
    "282": "transmembrane pore-forming viral proteins",
    "283": "Betacoronavirus",
    "284": "Coronaviridae",
    "285": "is an enveloped virus",
    "287": "single-stranded",
    "288": "8,098",
    "289": "9.6%,",
    "290": "interleukin 1 beta (IL-1β) and IL-",
    "292": "by sensing the cellular damage or distress induced by viroporins",
    "293": "76",
    "294": "Ca 2+ -permeable",
    "296": "the NLRP3 inflammasome",
    "257": "7.3 billion",
    "248": "Middle East respiratory syndrome coronavirus",
    "249": "Transmissibility and severity",
    "250": "January 30, 2020",
    "251": "H7N9",
    "252": "10",
    "253": "proportion of individuals who become ill with or die from a disease in a population",
    "254": "20%",
    "255": "number of additional persons one case infects over the course of their illness",
    "1657": "35 000 to 60 000",
    "1635": "homeostasis, differentiation, embryonic development, and organ physiology",
    "3258": "Nuclear receptors (NRs)",
    "3259": "a class of ligand-inducible transcription factors",
    "3260": "homeostasis, differentiation, embryonic development, and organ physiology",
    "3261": "seven",
    "3262": "a reliable 3D (three dimensional) structure of the target protein",
    "3263": "X-ray crystallography",
    "3264": "it is time-consuming and expensive",
    "3265": "membrane proteins",
    "3266": "KEGG (Kyoto Encyclopedia of Genes and Genomes)",
    "546": "HFRS",
    "547": "enveloped, negative-sense RNA virus",
    "548": "rodents",
    "549": "plasma viral load",
    "551": "as an antiviral medicine in many diseases",
    "552": "the plasma viral load",
    "554": "IFITM1, 2, and 3",
    "555": "the restriction of viral entry into cells",
    "556": "C allele",
    "2754": "RP transmission model",
    "2755": "Reservoir-People (RP) transmission network model",
    "2756": "2.30 from reservoir to person and 3.58 from person to person",
    "2757": "Our",
    "2758": "calculating the basic reproduction number (R 0 )",
    "2759": "The transmission network of Bats-Host was ignored.",
    "2760": "susceptible bats (S B ), exposed bats (E B ),",
    "2761": "four",
    "2762": "the seafood market) was denoted as W",
    "2763": "five compartments",
    "2764": "5.2 days",
    "2765": "5-day",
    "2766": "3 to 7 days",
    "2767": "5.8 days",
    "2768": "0.5 times that of symptomatic infection",
    "2769": "0.3 million",
    "2770": "2.87 million",
    "2771": "basic reproduction number",
    "2772": "2.30 from reservoir to person and 3.58 from person to person",
    "2773": "0.8-1.3",
    "2774": "2.5-7.2",
    "2775": "to decrease R 0 .",
    "2776": "that the transmissibility",
    "2777": "to provide a mathematical model for calculating the transmissibility",
    "5149": "cause viral hemorrhagic fevers (VHFs)",
    "5150": "Old World (OW) and New World (NW)",
    "5151": "The OW Lassa virus",
    "5152": "live attenuated",
    "5153": "because lung epithelial cells are one of the initial cell targets",
    "5154": "2 h",
    "5155": "Ouabain",
    "5156": "ATP1A1",
    "5157": "Combination therapy",
    "5158": "ATP1A1 and PHB",
    "5159": "using genetics and pharmacological inhibition of the genes",
    "5175": "mild skin infections to fatal necrotizing pneumonia",
    "5176": "8-30%",
    "5177": "tissue resident alveolar macrophages",
    "5178": "subsequent infection with Gram-positive bacteria, e.g., pneumococci",
    "5179": "Reduced TNFα production by NK cells",
    "5180": "dPly",
    "5181": "epithelial barrier damage, exaggerated innate immune response, and cytokine storm",
    "568": "interferon-induced transmembrane",
    "569": "three",
    "570": "2BP",
    "571": "IFITM5 with FKBP11",
    "572": "induces the expression of immunologically relevant genes",
    "573": "S-palmitoylation on the protein",
    "574": "bonerestricted IFITM-like (BRIL) protein",
    "575": "upstream of the ifitm5 gene lacks the interferon regulatory elements",
    "576": "65% similarity",
    "577": "65% similarity",
    "580": "aspartate-rich domain",
    "5256": "11 June 2009",
    "5257": "1/40",
    "5258": "conferring 50% protection against a viral challenge",
    "5259": "were based only on serological analysis of paired sera",
    "5260": "not de novo antibodies triggered by the pandemic virus",
    "5261": "week 38",
    "3267": "11,399",
    "3268": "49.2%",
    "3269": "2.2%)",
    "3270": "2005",
    "3271": "cough, rhinitis, fever and other common clinical symptoms",
    "3272": "(≤14 years old",
    "3273": "1.82:1",
    "4077": "compare the diagnostic performance between PCR/ESI-MS and conventional culture methods",
    "4078": "1 (2.4%)",
    "4079": "4.1% of cases",
    "4080": "parainfluenza infection, old age, and immunosuppression",
    "4081": "PCR/ ESI-MS",
    "4082": "if the patients met one of the following conditions",
    "4083": "9-month",
    "4084": "263",
    "4085": "rhinovirus",
    "917": "around 31 kb",
    "918": "single-stranded, linear, and nonsegmented RNA",
    "919": "30,847",
    "920": "20kb nucleotides",
    "921": "5=",
    "502": "Pneumonia",
    "504": "Improved socioeconomic status and vaccinations",
    "507": "up to 81%",
    "510": "605 million in 2000 to 664 million in 2015",
    "511": "The overall burden of childhood pneumonia has been reduced substantially over the last decade",
    "512": "25%",
    "513": "0.015 episodes per child year",
    "514": "81%",
    "515": "almost 10-fold higher",
    "516": "can also lead to significant morbidity and chronic disease",
    "517": "14% after an episode of hospitalized pneumonia",
    "518": "Chest radiologic changes",
    "520": "New conjugate vaccines",
    "521": "18%",
    "522": "presumed bacterial pneumonia",
    "524": "had a vaccine efficacy of 22% in preventing presumed bacterial pneumonia",
    "530": "pneumococcal serotypes not included in pneumococcal conjugate vaccination",
    "532": "decreased by 50% in children younger than 5 years",
    "533": "ambulatory pneumonia",
    "534": "S. pneumoniae and H. influenzae type B",
    "535": "many women of child-bearing age have waning pertussis antibody levels",
    "536": "a major cause of morbidity and mortality",
    "537": "HIV infection",
    "538": "increases odds of pneumonia by 1.6 times",
    "539": "Markers of undernutrition",
    "540": "68%.",
    "541": "Influenza vaccination during pregnancy is safe",
    "923": "a rare complication of pneumonia",
    "4573": "a dense or fluffy opacity",
    "5163": "accumulation of point mutations on immunodominant regions of surface proteins",
    "5164": "a positive-sense single stranded RNA enveloped virus",
    "5165": "about 3,000 aminoacids",
    "5166": "NS1 and NS2",
    "5167": "its high mutation rate that gives rise to highly diversified viral variants",
    "5168": "envelope glycoproteins E1 and E2",
    "5169": "based on antigenic differences of their nucleoprotein and matrix protein",
    "5170": "influenza A",
    "2477": "severe joint pain, contorting its victims into unusual postures",
    "2471": "Chikungunya fever (CHIKF),",
    "2470": "a mosquito-borne emerging pathogen",
    "2472": "Currently, there is no vaccine or antiviral treatment",
    "2473": "nominates a possible vaccine approach against CHIKV infection.",
    "2474": "a mosquito-borne emerging pathogen",
    "2475": "a mosquito-borne pathogen",
    "2476": "primarily by Aedes aegypti",
    "2478": "Kimakonde",
    "2479": "''that which contorts or bends up''",
    "2480": "the illness of the bended walker''",
    "2481": "in a sylvatic cycle",
    "2482": "Ae. aegypti and Ae. albopictus",
    "2483": "in an urban cycle whereby",
    "2484": "epidemic of CHIKV in La Reunion islands in the Indian Ocean",
    "2485": "46,000",
    "2486": "the epidemiology and global expansion of CHIKV",
    "2487": "the epidemiology and global expansion of CHIKV",
    "2488": "three",
    "2489": "Asian, East/Central/ South African, and West African",
    "2490": "between 50 and 310 y ago",
    "2491": "between 50 and 310 y ago",
    "2492": "has continued to wreak epidemics in several regions",
    "2493": "the Indian epidemic in 2005-2006",
    "2494": "the Kerala isolate",
    "2495": "2-6 d",
    "2496": "4-7 d",
    "2497": "The first stage is acute, while the second stage",
    "2498": "decreased dexterity, loss of mobility, and delayed reaction",
    "2499": "40%",
    "2500": "polyarthralgia",
    "2501": "children",
    "2502": "contorting its victims into unusual postures",
    "2503": "More than 50%",
    "2504": "more than 33%",
    "2505": "children",
    "2506": "respiratory failure, cardiovascular decompensation, meningoencephalitis",
    "2507": "complex replication cycle",
    "2508": "CHIKV with an alanine",
    "2509": "resulted in an ecological pressure",
    "2510": "to supplement Ae. aegypti as its primary vector",
    "2511": "Ae. albopictus",
    "2512": "over one-third of the island's population",
    "2513": "Asia, Africa, and parts of Europe",
    "2514": "Ae. albopictus became the main vector for CHIKV",
    "2515": "an increase in infectivity of Ae. albopictus",
    "2516": "Ae. albopictus",
    "2517": "100 times more infective",
    "2518": "Ae. albopictus",
    "2519": "over 300 y",
    "2520": "common in urban areas",
    "2521": "50%",
    "2522": "causing congenital illness and fetal death",
    "2523": "it is associated with a high degree of morbidity",
    "2524": "motherto-child transmission most likely happens transplacentally shortly before delivery",
    "2525": "nineteen cases of neonatal infection",
    "2526": "nominates a possible vaccine approach against CHIKV infection.",
    "2527": "nominates a possible vaccine approach against CHIKV infection.",
    "2528": "Category C Priority Path",
    "2529": "have an improved safety profile as compared to live or attenuated vaccines",
    "4221": "Wuhan, Hubei Province, China",
    "328": "bronchitis, pneumonia and bronchiolitis",
    "329": "bronchitis, pneumonia and bronchiolitis",
    "330": "NK cells (CD3-/CD16+/CD56+),",
    "331": "Excessive reactive oxygen species (ROS)",
    "332": "ROS"
}